Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized discontinuation trial of amifampridine phosphate in Lambert-Eaton myasthenic syndrome
2010-021850-20Phase 3Completed
- Sponsor
- Catalyst Pharmaceuticals
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lambert-Eaton myasthenic syndrome (LEMS) comparing Amifampridine continuation with Placebo discontinuation (2 arms). Started May 2011; status: completed.
02
Drugs
amifampridine
03
Conditions
Lambert-Eaton myasthenic syndrome (LEMS)
Beyond the preview
Go deeper on 2010-021850-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021850-20.